End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study
- PMID: 31133590
- PMCID: PMC6538204
- DOI: 10.1136/bmjopen-2018-027229
End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study
Abstract
Objectives: Central America is a region with an elevated burden of chronic kidney disease (CKD); however, the cost of treatment for end-stage renal disease (ESRD) remains an understudied area. This study aimed to investigate the direct costs associated with haemodialysis (HD) and peritoneal dialysis (PD) in public and private institutions in Panama in 2015, to perform a 5-year budget impact analysis and to calculate the years of life lost (YLL) due to CKD.
Design: A retrospective cost-analysis study using hospital costs and registry-based data.
Setting: Data on direct costs were derived from the public and private sectors from two institutions from Panama. Data on CKD-related mortality were obtained from the National Mortality Registry.
Methods: A budget impact analysis was performed from the payer perspective, and five scenarios were estimated, with the assumption that the mix of dialysis modality use shifts towards a greater use of PD over time. The YLL due to CKD was calculated using data recorded between 1 January 2015 and 31 December 2015. The linear method was utilised for the analyses with the population aged 20-77 years old.
Results: In 2015, the total costs for dialysis in the public sector ranged from ~US$7.9 million (PD) to US$62 million (HD). The estimated costs were higher in the scenario in which a decrease in PD was assumed. The average annual loss due to CKD was 25 501 808.40 US$-YLL.
Conclusion: ESRD represents a major challenge for Panama. Our results suggest that an increased use of PD might provide an opportunity to substantially lower overall ESRD treatment costs.
Keywords: chronic renal failure; costs; dialysis; panama; years of life lost.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: IMV, RV, BG, JM, CC and VH-B declare no conflict of interest. MTC currently works at Sanofi Pasteur, nonetheless, her responsibilities do not relate with the submitted work.
Figures


Similar articles
-
Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.Nephrol Dial Transplant. 2019 Sep 1;34(9):1565-1576. doi: 10.1093/ndt/gfy395. Nephrol Dial Transplant. 2019. PMID: 30668781
-
Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.BMC Health Serv Res. 2020 Feb 14;20(1):122. doi: 10.1186/s12913-020-4960-x. BMC Health Serv Res. 2020. PMID: 32059726 Free PMC article.
-
Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.BMJ Open. 2016 Oct 7;6(10):e012062. doi: 10.1136/bmjopen-2016-012062. BMJ Open. 2016. PMID: 27855091 Free PMC article.
-
Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.Nephrol Dial Transplant. 1999;14 Suppl 6:31-41. doi: 10.1093/ndt/14.suppl_6.31. Nephrol Dial Transplant. 1999. PMID: 10528710 Review.
-
Budgetary impact of increasing use of peritoneal dialysis over haemodialysis in Spain.Health Econ Rev. 2025 Apr 26;15(1):39. doi: 10.1186/s13561-025-00633-8. Health Econ Rev. 2025. PMID: 40285948 Free PMC article. Review.
Cited by
-
Risk of COVID-19 and Cost Burden in End-Stage Renal Disease Patients and Policy Implications for Managing Nephrology Services during the COVID-19 Pandemic.Healthcare (Basel). 2022 Nov 23;10(12):2351. doi: 10.3390/healthcare10122351. Healthcare (Basel). 2022. PMID: 36553874 Free PMC article.
-
Psychosocial, Spiritual, and Biomedical Predictors of Hope in Hemodialysis Patients.Int J Nephrol Renovasc Dis. 2020 Jun 26;13:163-169. doi: 10.2147/IJNRD.S255045. eCollection 2020. Int J Nephrol Renovasc Dis. 2020. PMID: 32617015 Free PMC article.
-
Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis.Avicenna J Phytomed. 2022 Nov-Dec;12(6):576-588. doi: 10.22038/AJP.2022.20049. Avicenna J Phytomed. 2022. PMID: 36583173 Free PMC article. Review.
-
Solution-Focused Group Counseling on Mental States in Hemodialysis Patients with Anxiety.Actas Esp Psiquiatr. 2024 Apr;52(2):122-129. doi: 10.62641/aep.v52i2.1562. Actas Esp Psiquiatr. 2024. PMID: 38622009 Free PMC article.
-
The economic value of personal protective equipment for healthcare workers.PLOS Glob Public Health. 2023 Jun 22;3(6):e0002043. doi: 10.1371/journal.pgph.0002043. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37347760 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical